Skip to main content

Once Health Canada has approved a drug for use in Canada, the country’s public drug programs and cancer agencies must decide if the drug will be eligible for public reimbursement.

CADTH conducts evaluations to provide reimbursement recommendations and advice to federal and provincial public drug plans.

Canadian Myeloma Research Group prepares and submits the necessary input to the CADTH drug reimbursement review process to ensure that most advanced and effective myeloma treatments are available to the Canadian patients